BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 25.05.2021

Bispecific Antibody Development Programs; Guidance for Industry; Availability

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Bispecific Antibody Development Programs." This guidance provides recommendations to assist industry and other parties involved in the development of bispecific antibodies. The guidance focuses on general regulatory and scientific considerations for bispecific antibodies, but not on development of a particular bispecific antibody. This guidance finalizes the draft guidance of the same title issued on April 19, 2019.

Source: Federal Register — Food and Drug AdministrationOpen original release →